Compare ROC & VRCA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ROC | VRCA |
|---|---|---|
| Founded | 2015 | 2013 |
| Country | United States | United States |
| Employees | 82 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 100.6M | 117.5M |
| IPO Year | N/A | 2018 |
| Metric | ROC | VRCA |
|---|---|---|
| Price | $5.12 | $6.40 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 2 |
| Target Price | $9.00 | ★ $17.00 |
| AVG Volume (30 Days) | ★ 66.3K | 38.9K |
| Earning Date | 03-31-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $35,577,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $94.44 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 370.22 |
| 52 Week Low | $3.71 | $0.72 |
| 52 Week High | $7.80 | $9.82 |
| Indicator | ROC | VRCA |
|---|---|---|
| Relative Strength Index (RSI) | 51.38 | 52.37 |
| Support Level | $4.42 | $5.32 |
| Resistance Level | $5.32 | $6.56 |
| Average True Range (ATR) | 0.60 | 0.55 |
| MACD | 0.03 | 0.05 |
| Stochastic Oscillator | 62.61 | 59.02 |
Rank One Computing Corp is an American artificial intelligence company. It develops AI systems that analyze visual data to identify and interpret objects and activities. The company's focus is on biometric identity, digital forensics, and real-time video analytics. It uses the term 'Vision AI,' which is an operational AI built for accuracy, speed, and auditability. The company generates revenue from the sale of access to its software platforms, maintenance services, and professional services.
Verrica Pharmaceuticals Inc is a therapeutics company developing and commercializing medications for the treatment of dermatologic diseases, including skin cancers. Its commercial product and portfolio of product candidates are clinician administered therapies in areas of high unmet need. This product portfolio consists of one product with an approved indication for molluscum contagiosum, or molluscum, with the potential for several follow-on indications, as well as additional pipeline product candidates. Its commercial product, YCANTH (VP-102), for the treatment of molluscum in adult and pediatric patients two years of age and older. YCANTH (VP-102) is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin.